These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 19052118)

  • 21. Inhibition of Taq polymerase as a method for screening heparin for oversulfated contaminants.
    Tami C; Puig M; Reepmeyer JC; Ye H; D'Avignon DA; Buhse L; Verthelyi D
    Biomaterials; 2008 Dec; 29(36):4808-14. PubMed ID: 18801571
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthetic heparin analogue and prothrombin time.
    Kakkar VV; Djazaeri B; Scully M; Weerasinghe K
    Lancet; 1981 May; 1(8230):1167. PubMed ID: 6112524
    [No Abstract]   [Full Text] [Related]  

  • 23. Electrophoresis for the analysis of heparin purity and quality.
    Volpi N; Maccari F; Suwan J; Linhardt RJ
    Electrophoresis; 2012 Jun; 33(11):1531-7. PubMed ID: 22736353
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Heparin comes clean.
    Schwartz LB
    N Engl J Med; 2008 Jun; 358(23):2505-9. PubMed ID: 18525048
    [No Abstract]   [Full Text] [Related]  

  • 25. Assessment of oversulfated chondroitin sulfate in low molecular weight and unfractioned heparins diffusion ordered nuclear magnetic resonance spectroscopy method.
    Sitkowski J; Bednarek E; Bocian W; Kozerski L
    J Med Chem; 2008 Dec; 51(24):7663-5. PubMed ID: 19055319
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tools for the Quality Control of Pharmaceutical Heparin.
    Devlin A; Mycroft-West C; Procter P; Cooper L; Guimond S; Lima M; Yates E; Skidmore M
    Medicina (Kaunas); 2019 Sep; 55(10):. PubMed ID: 31557911
    [TBL] [Abstract][Full Text] [Related]  

  • 27. From crisis to opportunity: a perspective on the heparin crisis.
    Sasisekharan R; Shriver Z
    Thromb Haemost; 2009 Nov; 102(5):854-8. PubMed ID: 19888519
    [No Abstract]   [Full Text] [Related]  

  • 28. An assessment of polydispersed species in unfractionated and low molecular weight heparins by diffusion ordered nuclear magnetic resonance spectroscopy method.
    Bednarek E; Sitkowski J; Bocian W; Mulloy B; Kozerski L
    J Pharm Biomed Anal; 2010 Nov; 53(3):302-8. PubMed ID: 20417048
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Increased prevalence of antiheparin platelet factor 4 antibodies in patients may be due to contaminated heparin.
    Adiguzel C; Bansal V; Litinas E; Cunanan J; Iqbal O; Nelson K; Kannan M; Hoppensteadt D; Fareed J
    Clin Appl Thromb Hemost; 2009; 15(2):145-51. PubMed ID: 19357103
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Determination of oversulfated chondroitin sulfate and dermatan sulfate impurities in heparin by capillary electrophoresis.
    Somsen GW; Tak YH; Toraño JS; Jongen PM; de Jong GJ
    J Chromatogr A; 2009 May; 1216(18):4107-12. PubMed ID: 19272607
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Contaminants in heparins continue to be unfolded.
    Fareed J; Ahluwalia M; Wahi R; Ramaccioti E; Hoppensteadt D; Bick RL
    Int Angiol; 2008 Dec; 27(6):457-61. PubMed ID: 19078906
    [No Abstract]   [Full Text] [Related]  

  • 32. Isolation and characterization of contaminants in recalled unfractionated heparin and low-molecular-weight heparin.
    Viskov C; Bouley E; Hubert P; Martinez C; Herman F; Jeske W; Hoppensteadt D; Walenga JM; Fareed J
    Clin Appl Thromb Hemost; 2009; 15(4):395-401. PubMed ID: 19617248
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [NMR analysis of a contaminant in heparin].
    Yamaguchi H; Shinagawa M; Shimba N; Miyano H; Suzuki E
    Yakugaku Zasshi; 2008 Oct; 128(10):1513-5. PubMed ID: 18827473
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Milk adulterated with melamine: another scandal in public health].
    Astier A
    Ann Pharm Fr; 2009 Jan; 67(1):1-2. PubMed ID: 19152844
    [No Abstract]   [Full Text] [Related]  

  • 35. Effect of Ca2+ on the 1H NMR chemical shift of the methyl signal of oversulphated chondroitin sulphate, a contaminant in heparin.
    McEwen I; Rundlöf T; Ek M; Hakkarainen B; Carlin G; Arvidsson T
    J Pharm Biomed Anal; 2009 Apr; 49(3):816-9. PubMed ID: 19179033
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Source-induced fragmentation of heparin, heparan, and galactosaminoglycans and application.
    Hu P; Fang L; Chess EK
    Anal Chem; 2009 Mar; 81(6):2332-43. PubMed ID: 19228018
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Analysis of heparin sodium by SAX/HPLC for contaminants and impurities.
    Trehy ML; Reepmeyer JC; Kolinski RE; Westenberger BJ; Buhse LF
    J Pharm Biomed Anal; 2009 Apr; 49(3):670-3. PubMed ID: 19167854
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect of acetaldehyde-glycosaminoglycan mixtures upon Factor IXa and Factor IX-Deficient Plasma.
    Brecher AS; Moon AR; Gray KD
    Alcohol; 2006 Jun; 39(2):97-104. PubMed ID: 17134662
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification and purity test of heparin by NMR - a summary of two years' experience at the Medical Products Agency.
    McEwen I; Amini A; Olofsson IM
    Pharmeur Bio Sci Notes; 2010 Apr; 2010(1):65-72. PubMed ID: 20223191
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fucosylated chondroitin sulfate as a new oral antithrombotic agent.
    Fonseca RJ; Mourão PA
    Thromb Haemost; 2006 Dec; 96(6):822-9. PubMed ID: 17139379
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.